Bio Business

» tuberculosis and disease/medicine

Most Recent

image: Desperately Seeking Shut-Eye

Desperately Seeking Shut-Eye

By | March 1, 2016

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Picking Up the Pace

Picking Up the Pace

By | January 1, 2016

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Battling the Bulge

Battling the Bulge

By | November 1, 2015

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Clinical Matchmaker

Clinical Matchmaker

By | June 1, 2015

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

1 Comment

image: Eyes on the Prize

Eyes on the Prize

By | October 1, 2014

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

3 Comments

image: That Loving Feeling

That Loving Feeling

By | July 1, 2014

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

1 Comment

image: Outwitting the Perfect Pathogen

Outwitting the Perfect Pathogen

By | January 1, 2014

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Remaking a Classic

Remaking a Classic

By | September 1, 2013

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: A Dime a Dozen

A Dime a Dozen

By | January 1, 2013

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech